Drug Discovery

Mallinckrodt agrees to sell hemostasis products to Baxter

Mallinckrodt has agreed to divest several hemostasis products to Baxter International for about $185m, with upfront payment of $153m, inclusive of existing inventory, and the remainder in potential future milestones

Ablynx rejects EUR2.6bn takeover offer from Novo Nordisk

Ablynx has rejected a takeover proposal of around €2.6bn from Novo Nordisk, calling it as unsolicited and it fundamentally undervalues the company.

Takeda proposes to buy cell therapy firm TiGenix for EUR520m

Takeda Pharmaceutical has offered to acquire Belgium-based cell therapy company TiGenix for €520m to expand its late-stage gastroenterology pipeline and its footprint in the US specialty care market.

Sangamo, Pfizer collaborate to develop zinc finger protein gene therapy for ALS

Sangamo Therapeutics and Pfizer have collaborated for the development of a potential gene therapy using zinc finger protein transcription factors (ZFP-TFs) to treat amyotrophic lateral sclerosis (ALS) and frontotemporal lobar degeneration (FTLD) linked to mutations of the C9ORF72 gene.

NovaQuest Capital to buy Viamet Pharmaceuticals

NovaQuest Capital Management has agreed to acquire Viamet Pharmaceuticals, including its product candidate, VT-1161, which has completed Phase 2b clinical trials for the treatment of recurrent vulvovaginal candidiasis (RVVC) and onychomycosis, or fungal nail infection.

Mylan launches Estrace Cream generic after FDA approval

Mylan has launched Estradiol Vaginal Cream USP, 0.01%, the first generic version of Allergan's Estrace Cream, in the US.

Summit signs deal with Eurofarma for Latin American rights to Ridinilazole

Summit Therapeutics has entered into an exclusive licence and commercialization agreement with Eurofarma Laboratórios, granting rights in Latin America to Summit's precision antibiotic ridinilazole in development for the treatment of CDI.

vTv grants GLP-1r agonist diabetes program rights in China to Hangzhou Zhongmei

vTv Therapeutics has entered into a licensing agreement with Hangzhou Zhongmei Huadong Pharmaceutical for rights to develop and commercialize the former’s GLP-1r agonist program in China and other Pacific Rim countries.

MilliporeSigma signs commercial supply agreement with bluebird bio for viral vector manufacturing

MilliporeSigma has signed a commercial supply agreement to manufacture viral vectors for bluebird bio for use in potentially transformative gene therapies.